Biodesix (BDSX) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Biodesix (BDSX) has outperformed Myriad Genetics (MYGN) over the past year, gaining 232.3% versus a loss of 44.3%. Over five years, BDSX leads with a -82.7% price change compared with -86.4% for MYGN. Myriad Genetics is the larger company by market cap ($412.2 million vs $274.5 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDSX | MYGN |
|---|---|---|
| Share price | $26.02 | $4.31 |
| Market cap | $274.54M | $412.25M |
| 1-day change | +1.52% | +2.62% |
| YTD return | +282.65% | -29.92% |
| 1-year return | +232.31% | -44.32% |
| 5-year return | -82.65% | -86.42% |
| EPS (TTM) | $-3.14 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.97 | $8.59 |
| 52-week low | $5.26 | $2.74 |
| Distance from 52-week high | -18.61% | -49.83% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +43.47% | -9.28% |
| Average volume | 100.90K | 2.04M |
| Shares outstanding | 10.55M | 95.65M |
| Employees | 334 | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BDSX has outperformed MYGN by 276.6 percentage points over the past year.
About Biodesix
BDSX stock →Biodesix, Inc. operates as a diagnostic solutions company.
Health Care · Medical Specialities · 334 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
BDSX vs MYGN FAQ
Which is bigger, Biodesix or Myriad Genetics?
Myriad Genetics (MYGN) is larger, with a market capitalization of $412.25M compared with $274.54M for Biodesix (BDSX).
Which stock has performed better over the past year, BDSX or MYGN?
BDSX returned +232.31% over the past 12 months, compared with -44.32% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Biodesix and Myriad Genetics in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Biodesix and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Myriad Genetics.